Condition
Ripertamab
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 1 (1)
Trial Status
Not Yet Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT07685678Phase 1Not Yet Recruiting
Study on Efficacy Evaluation of Ripertamab in the Treatment of Neuromyelitis Optica Spectrum Disorders
NCT07388810Not ApplicableNot Yet Recruiting
Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome
Showing all 2 trials